Stock comparison
Halozyme Therapeutics
IRadimed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
IRMD
IRadimed
Market cap
$1.18B
Sector
Healthcare
Overall winner
IRadimed IRMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | IRMD | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 68B | HALO |
| Benjamin Graham | 83A | 89A | IRMD |
| Philip Fisher | 65B | 92A | IRMD |
| Peter Lynch | 53D | 76B | IRMD |
| Joel Greenblatt | 40D | 65C | IRMD |
| Charlie Munger | 80C | 78B | HALO |
| Terry Smith | 84A | 75B | HALO |
Side-by-side metrics
| Metric | HALO | IRMD |
|---|---|---|
| Market cap | $8.1B | $1.18B |
| P/E (TTM) | 24.0x | 50.4x |
| EV/EBIT | 10.2x | 43.4x |
| ROIC (TTM) | 23.65% | 21.38% |
| Gross margin | 81.24% | 76.84% |
| Net margin | 23.13% | 27.36% |
| Revenue CAGR 5y | 33.23% | 18.99% |
| EPS CAGR 5y | -1.98% | 23.53% |
| Debt / Equity | 1.0x | - |
| Dividend yield | 0.0% | 1.33% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Market cap$8.1Bvs $1.18B+85%
- EV/EBIT10.2xvs 43.4x+77%
- P/E (TTM)24.0xvs 50.4x+52%
- Revenue CAGR 5y33.23%vs 18.99%+43%
IRMD leads on
- EPS CAGR 5y23.53%vs -1.98%+108%
- Debt / Equity-vs 1.0x+100%
- Dividend yield1.33%vs 0.0%+100%
- Net margin27.36%vs 23.13%+15%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.